---
figid: PMC4212018__nihms595549f1
figtitle: Adaptive resistance to RAF inhibitors in melanoma
organisms:
- Homo sapiens
- Mus musculus
- Diaporthe sclerotioides
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC4212018
filename: nihms595549f1.jpg
figlink: /pmc/articles/PMC4212018/figure/F1/
number: F1
caption: '(Left) ERK1/2 pathway inhibition by vemurafenib leads to downregulation
  of DUSP and SPRY proteins. Loss of SPRY results in more efficient NRAS activation
  leading to a reactivation of the ERK1/2 pathway. This is enhanced by reduced ERK1/2
  dephosphorylation resulting from lower levels of DUSP proteins. (Middle) Vemurafenib
  treatment increases PDGFRβ and ERBB3 leading to activation of the AKT pathway and
  promoting resistance to ERK1/2 pathway inhibition. (Right) Increased levels of JARID1B
  and PGC1α following ERK1/2 pathway inhibition leads to a metabolic switch from glycolysis
  to oxidative phosphorylation promoting resistance to RAF inhibition. Abbreviations
  used are: EGFR, epidermal growth factor receptor; GRB2, growth factor receptor-bound
  protein 2; SOS, son of sevenless; NRAS, neuroblastoma RAS viral oncogene homolog;
  BRAF, v-Raf murine sarcoma viral oncogene homolog B1; CRAF, v-Raf-1 murine leukemia
  viral oncogene homolog 1; MEK, mitogen-activated protein kinase kinase; ERK, extracellular
  signal-regulated kinase; DUSP, dual-specificity phosphatase; SPRY, sprouty; PDGFRβ,
  platelet-derived growth factor receptor, beta polypeptide; ERBB3, v-erb-b2 avian
  erythroblastic leukemia viral oncogene homolog 3; ERBB2, v-erb-b2 avian erythroblastic
  leukemia viral oncogene homolog 2; PI-3K, phosphatidylinositol 3-kinase; AKT, v-akt
  murine thymoma viral oncogene; FOXD3, forkhead box transcription factor D3; JARID1B,
  lysine-specific demethylase 5B; MITF, microphthalmia-associated transcription factor;
  PGC1α, peroxisome proliferator-activated receptor gamma coactivator 1 alpha.'
papertitle: Adaptive resistance to RAF inhibitors in melanoma.
reftext: Curtis H. Kugel, et al. Pigment Cell Melanoma Res. ;27(6):1032-1038.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9670371
figid_alias: PMC4212018__F1
figtype: Figure
redirect_from: /figures/PMC4212018__F1
ndex: 475c772a-decf-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4212018__nihms595549f1.html
  '@type': Dataset
  description: '(Left) ERK1/2 pathway inhibition by vemurafenib leads to downregulation
    of DUSP and SPRY proteins. Loss of SPRY results in more efficient NRAS activation
    leading to a reactivation of the ERK1/2 pathway. This is enhanced by reduced ERK1/2
    dephosphorylation resulting from lower levels of DUSP proteins. (Middle) Vemurafenib
    treatment increases PDGFRβ and ERBB3 leading to activation of the AKT pathway
    and promoting resistance to ERK1/2 pathway inhibition. (Right) Increased levels
    of JARID1B and PGC1α following ERK1/2 pathway inhibition leads to a metabolic
    switch from glycolysis to oxidative phosphorylation promoting resistance to RAF
    inhibition. Abbreviations used are: EGFR, epidermal growth factor receptor; GRB2,
    growth factor receptor-bound protein 2; SOS, son of sevenless; NRAS, neuroblastoma
    RAS viral oncogene homolog; BRAF, v-Raf murine sarcoma viral oncogene homolog
    B1; CRAF, v-Raf-1 murine leukemia viral oncogene homolog 1; MEK, mitogen-activated
    protein kinase kinase; ERK, extracellular signal-regulated kinase; DUSP, dual-specificity
    phosphatase; SPRY, sprouty; PDGFRβ, platelet-derived growth factor receptor, beta
    polypeptide; ERBB3, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog
    3; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; PI-3K,
    phosphatidylinositol 3-kinase; AKT, v-akt murine thymoma viral oncogene; FOXD3,
    forkhead box transcription factor D3; JARID1B, lysine-specific demethylase 5B;
    MITF, microphthalmia-associated transcription factor; PGC1α, peroxisome proliferator-activated
    receptor gamma coactivator 1 alpha.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - PDGFRB
  - ERBB2
  - EGFR
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - GRB2
  - XYLT2
  - SOS1
  - SOS2
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - ERBB3
  - DUSP5
  - DUSP1
  - DUSP2
  - DUSP3
  - DUSP4
  - DUSP6
  - KDM5B
  - SPRY1
  - SPRY2
  - SPRY3
  - SPRY4
  - MITF
  - PPARGC1A
  - ZHX2
  - ARAF
  - Mapk3
  - Akt1
  - Pdgfrb
  - Erbb2
  - Egfr
  - Nras
  - Pik3r1
  - Grb2
  - Braf
  - Braf-rs1
  - Raf1
  - Mdk
  - Ephb2
  - Mapk1
  - Erbb3
  - Kdm5b
  - Mitf
  - Tff3
  - Naip3
  - Ppargc1a
  - Zhx2
  - rl
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - drk
  - Sos
  - Dsor1
  - Mtk
  - pho
  - ox
  - Erk7
  - usp
  - sty
  - srl
  - Raf
  - Cancer
  - Lung cancer
  - Noonan syndrome
---
